2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3